AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Igo et al.						Docket No. PR60364USW	
	T				\pm		
Application No.	Filing Date	Examiner		Customer N	٥.	Group Art Unit	Confirmation No.
10/565,294	1/20/06	J. Nolan		23347		1626	7095
Invention: (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-I-PHENYLALANYL]-2-PYRROLIDINEC ARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF							
COMMISSIONER FOR PATENTS:							
Transmitted herewith is an amendment in the above-identified application.							
The fee has been o	calculated and is trans	mitted as shown below.					
CLAIMS AS AMENDED							
	CLAIMS REMAINING	HIGHEST#	NUMBI	ER EXTRA		RATE	ADDITIONAL
	AFTER AMENDMENT	PREV. PAID FOR	CLAIMS	PRESENT	_		FEE
TOTAL CLAIMS	4 -	20 =		0	X	\$50.00	\$0.00
INDEP. CLAIMS 1 - 3 =				0	X	\$210.00	\$0.00 \$0.00
Multiple Dependent Claims (check if applicable) TOTAL ADDITIONAL FEE FOR THIS AMENDMENT							\$0.00
Please cha A check in A check in The Direct communic Any a Any p Payment b WARNING included of Robert (Steve) The Attorney for Appl GlaxoSmithKline Five Moore Drive,	ation or credit any ove dditional filing fees received application processor credit card. Form PT: Information on this on this form. Provide Signature omas, Reg. No. 52,284 icants PO Box 13398 le Park, NC 27709-339 483-8406	to cover the filing to cover the filing do to charge payment of rpayment to Deposit Acquired under 37 C.F.R. ressing fees under 37 C.F.C-2038. form may become puredit card information	fee is enthe following the following the following the feet the Unclass in the feet	by certify that hited States Ponail in an envelor ox 1450, Alexar	this stal	mation should n PTO-2038. correspondence is Service with suffi addressed to "Com, VA 22313-1450"	s being deposited with icient postage as first nmissioner for Patents, [37 CFR 1.8(a)] on
cc:				Signature of Person Mailing Correspondence Typed or Printed Name of Person Mailing Correspondence			